WO2016086554A1 - Anticorps monoclonal général de souches du virus de la peste porcine africaine ainsi que son procédé de préparation et application associée - Google Patents

Anticorps monoclonal général de souches du virus de la peste porcine africaine ainsi que son procédé de préparation et application associée Download PDF

Info

Publication number
WO2016086554A1
WO2016086554A1 PCT/CN2015/075183 CN2015075183W WO2016086554A1 WO 2016086554 A1 WO2016086554 A1 WO 2016086554A1 CN 2015075183 W CN2015075183 W CN 2015075183W WO 2016086554 A1 WO2016086554 A1 WO 2016086554A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
swine fever
african swine
fever virus
cells
Prior art date
Application number
PCT/CN2015/075183
Other languages
English (en)
Chinese (zh)
Inventor
曹琛福
花群义
吕建强
刘建利
宗卉
杨俊兴
张彩虹
孙洁
唐金明
廖立珊
Original Assignee
深圳出入境检验检疫局动植物检验检疫技术中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳出入境检验检疫局动植物检验检疫技术中心 filed Critical 深圳出入境检验检疫局动植物检验检疫技术中心
Publication of WO2016086554A1 publication Critical patent/WO2016086554A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Definitions

  • the present application relates to the field of monoclonal antibodies, and in particular to a universal monoclonal antibody for use in African swine fever virus strains, and a preparation method and application of the monoclonal antibodies.
  • African Swine Fever is an acute, heat, and highly contagious disease caused by African Swine Fever Virus (ASFV). Its clinical symptoms are hyperthermia, skin congestion, Abortion, edema and organ bleeding, the mortality rate is as high as 100%. However, after a small number of strains infected domestic pigs, pigs developed subacute infection or recessive poisoning. The World Organisation for Animal Health (OIE) listed it as a Class A animal disease, which has been highly valued by countries all over the world. The disease has not yet occurred in China. China has established this disease as a type of animal infectious disease and has been studied as an animal disease. Sun Huaichang. Chinese Journal of Preventive Veterinary Medicine, 1999, 21(21): 117-119).
  • African swine fever has spread from the African continent to Armenia, Ukraine, and Russia in the Eurasian continent.
  • the epidemic situation in the Caucasus in recent years is severe and poses a great threat to China.
  • the occurrence of African swine fever in Western Europe, South America and Eastern Europe has confirmed that the introduction of African swine fever will bring a devastating blow to the pig industry.
  • China has included African swine fever in the 2011 National Animal Disease Surveillance Program, and identified Xinjiang, Inner Mongolia, Heilongjiang, Jilin, Liaoning, and Vietnam as key monitoring provinces (Wang Hongyan, pig raising, 2011, 4:81-82).
  • the detection procedure cannot be standardized in clinical use, and the risk of active poisoning is large, so it is not suitable for popularization and application.
  • the development of detection methods and reagents mostly uses genetic engineering methods to express antigens, mainly focusing on the research of genes such as p72, p54, p32, pp62, A104R, B602L, K205R, among which p72, p54 and the like are widely used.
  • the preparation of monoclonal antibodies is also mainly concentrated on these structural proteins, and the commercial kits based on immunological methods thus established are currently only four in the world.
  • the existing commercial kits are prone to occur during use. The detection of African swine fever caused by some strains.
  • the purpose of the present application is to provide a novel monoclonal antibody against the African swine fever virus strain, and a preparation method and application of the universal monoclonal antibody.
  • the present invention discloses a method for preparing a universal monoclonal antibody of an African swine fever virus strain, which comprises immunizing a mouse with purified p54 immune protein, and merging the spleen cells of the immunized mouse with the mouse myeloma cells to prepare a hybrid. Tumor cells, then screened positive hybridoma cell lines using three screening antigens to obtain hybridoma cells stably secreting monoclonal antibodies against African swine fever virus, and then preparing African swine fever virus strains by in vivo or in vitro methods.
  • the three screening antigens include a prokaryotic expression p54 recombinant protein, a eukaryotic expression p54 recombinant protein, and a synthetic sequence of the sequence shown by Seq ID No. 1.
  • Seq ID No. 1 SSRKKKAAAA IEEE DIQFINPYQDQQWAEV.
  • the key of the present application is to screen hybridoma cell lines by using three screening antigens, wherein the artificially synthesized polypeptides represented by Seq ID No. 1 are specific to all existing African swine fever virus strains. Designed, the sequence is aligned in the NCBI database and shared by all African swine fever virus strains. Therefore, the monoclonal antibodies prepared by the hybridoma cell strains screened by them are versatile and can be used in different regions. Sources of African swine fever virus are tested to avoid missed detection.
  • the key to the present application is to screen hybridoma cell lines using three screening antigens, especially to artificially design a synthetic polypeptide, so that the prepared monoclonal antibody has versatility; as for p54 immune protein Preparation and purification, preparation of prokaryotic expression p54 recombinant protein, preparation of eukaryotic expression p54 recombinant protein, preparation of specific conditions and steps for merging hybridoma cells, immunoscreening of hybridoma cells, etc. can be carried out by referring to existing conventional methods. It is not exhaustive here.
  • the preparation method of the monoclonal antibodies in vivo or in vitro can also refer to existing conventional methods; for example, intraperitoneal injection of hybridoma cells into animals, such as In mice, ascites is collected, and the monoclonal antibody is isolated and purified; or, the monoclonal antibody produced by secretion is collected by in vitro culture of the hybridoma cells.
  • hybridoma cell line SZCIQASFV1 The hybridoma cells stably secreted against the monoclonal antibody against African swine fever virus are designated as hybridoma cell line SZCIQASFV1, and the microbial deposit number is: CCTCC No. C2014212; the classification is named: hybridoma cell hybridoma cell; preservation The time is: December 3, 2014; the depositary is: China's typical culture preservation center; the deposit address is: Wuhan Wuchang Wushan Wuhan University Depository Center, Hubei province.
  • the p54 immune protein is obtained by transferring the p54 gene fragment of the pMD18-T-p54 plasmid into the pET-52b(+) plasmid, and performing soluble expression in Escherichia coli DH5 ⁇ , and then extracting and purifying the expressed protein, ie, P54 immune protein.
  • the prokaryotic expression p54 recombinant protein is a purified p54 recombinant protein obtained by prokaryotic expression of pET-52b(+) plasmid in E. coli; eukaryotic expression of p54 recombinant protein is eukaryotic using pFastBac/NT-TOPO insect expression system The obtained p54 recombinant protein was expressed.
  • the other side of the application discloses a universal monoclonal antibody against the African swine fever virus strain which is secreted by the hybridoma cell line SZCIQASFV1 of accession number CCTCC No. C2014212.
  • the universal monoclonal antibody of the African swine fever virus strain of the present application is obtained by the preparation method of the present application.
  • a further aspect of the present application discloses the use of a universal monoclonal antibody of the present application in the preparation of an African swine fever virus detection reagent or device.
  • an African swine fever virus enzyme-linked immunosorbent assay kit comprising the universal monoclonal antibody of the present application is specifically disclosed.
  • the present application also provides a hybridoma cell which secretes a universal monoclonal antibody of the African swine fever virus strain of the present application, and has a accession number of CCTCC No. C2014212.
  • hybridoma cells of the universal monoclonal antibody secreting the African swine fever virus strain of the present application are, in fact, the stable secretory anti-Africa selected by the preparation method of the universal monoclonal antibody of the African swine fever virus strain.
  • hybridoma cells are screened by using three screening antigens, in particular, a polypeptide shared by all African swine fever virus strains is designed and synthesized as a screening antigen, so that the prepared monoclonal antibodies can be different.
  • the detection of geographically sourced African swine fever virus strains greatly reduces the phenomenon of missed detection caused by geographical differences between strains, and improves the quality and efficiency of inspection and quarantine work.
  • Figure 1 is a PCR identification result of the recombinant expression plasmid pET-52b(+)3C/LIC-p54 in the examples of the present application;
  • Figure 2 shows the results of SDS-PAGE analysis of the induced expression product of pET-52b(+)3C/LIC-p54 recombinant plasmid in BL21(DE3) in the examples of the present application;
  • Figure 3 is a result of purification and immunoblot analysis of the induced expression product of pET-52b(+)3C/LIC-p54 recombinant plasmid in BL21(DE3) in the examples of the present application;
  • Figure 4 is a PCR identification result of the pFastBac-p54 recombinant plasmid and the Bacmid-p54 recombinant cosmid in the examples of the present application;
  • Figure 5 is a Western-blot identification result of the pFastBac/NT-TOPO insect expression system eukaryotic expression p54 recombinant protein in the examples of the present application;
  • Figure 6 is a diagram showing the results of analyzing the affinity of the universal monoclonal antibody of the African classical swine fever virus strain and the specific antigen epitope polypeptide A in the African swine fever virus p54 protein by using the ProteinOn XPR36 macromolecular interaction instrument in the examples of the present application.
  • Figure 7 is a graph showing the results of an alignment analysis of the African swine fever virus p54 protein sequence in the examples of the present application.
  • the existing commercial kits are prone to missed detection during use; there is a need for a strain of African swine fever virus that is good for different geographical sources.
  • a monoclonal antibody that detects the effect. Therefore, the present application aims to develop a monoclonal antibody that can be used to establish a monoclonal antibody based on all known African swine fever virus strains that are currently prevalent worldwide.
  • Immunological methods such as competitive ELISA methods for antibodies provide key materials and methods to solve the problem of missed detection of existing commercial kits, and reduce or do not rely on foreign detection reagents, so that China has independent detection capabilities and detection reagents to prevent African swine fever The epidemic was introduced to China.
  • the present application specifically designs and artificially synthesizes a polypeptide shared by all known African swine fever virus strains, ie, the sequence represented by Seq ID No. 1, for hybridoma cell screening, and The prokaryotic expression of p54 recombinant protein and eukaryotic expression p54 recombinant protein were screened, so that the finally prepared monoclonal antibody can detect all known African swine fever virus strains, that is, the universal monoclonal antibody of African swine fever virus strain. antibody.
  • the artificially synthesized polypeptides as screening antigens are confirmed by NCBI database comparison. In theory, especially the monoclonal antibodies obtained by screening can detect all known African swine fever virus strains; the test in this application is also different. The strains from geographical origin were tested and the results were in agreement with the theory.
  • the polypeptide of the sequence shown in the synthetic Seq ID No. 1 is designed for the antigenic site "EDIQFINPYQ", and the sequence polypeptide represented by Seq ID No. 1 is designed to ensure the immune effect.
  • the sequence polypeptide represented by Seq ID No. 1 is designed to ensure the immune effect.
  • about 20 amino acids can be added or subtracted before and after the polypeptide sequence based on the sequence polypeptide represented by Seq ID No. 1. All of them belong to the protection scope of the present application; more amino acids may be added to the sequence polypeptide represented by Seq ID No. 1 of the present application without considering the cost of artificial synthesis.
  • the present application provides a universal monoclonal antibody against the African swine fever virus strain. And its applications. It can be understood that the monoclonal antibody of the present application has good versatility, can detect strains of different geographical origins, and greatly reduces the missed detection caused by the geographical difference of the strain; therefore, the kit can be widely used for preparing the kit. Inspection and quarantine work; the kit contains, in addition to the monoclonal antibody of the present application, of course, other conventional reagents for enzyme-linked immunoassay, which are not described herein.
  • a pair of primers were designed to amplify the target gene from the pMD18-T-p54 plasmid cloned with the African swine fever virus p54 gene.
  • the pMD18-T-p54 plasmid was saved and provided by the Animal and Plant Inspection and Quarantine Technology Center of Shenzhen Entry-Exit Inspection and Quarantine Bureau.
  • This plasmid contained a 552 bp p54 gene having the sequence shown as Seq ID No. 10.
  • the upstream primer of the primer was the sequence shown by Seq ID No. 2, and the downstream primer was the sequence shown by Seq ID No. 3.
  • Seq ID No. 2 5'-CAGGGACCCGGTTATACTATTCTCATTGCTATCG-3’
  • Seq ID No. 3 5'-GGCACCAGAGCGTTCAAGGAGTTTTCTAGGTC-3’
  • PCR amplification was carried out using the pMD18-T-p54 plasmid as a template.
  • the reaction conditions were 94 ° C for 1 min, 58 ° C for 1 min, 30 cycles, and 72 ° C for 5 min.
  • the product was amplified by 1.5% agarose gel electrophoresis, and the purified target DNA was recovered by a gel recovery kit to obtain a target gene.
  • T4 DNA polymerase to the target gene obtained in the above step, incubate at 22 °C for 30 min, incubate at 75 °C for 20 min, add 3C/LIC vector, incubate for 5 min at 22 °C, incubate for 5 min at 22 °C after adding EDTA, construct pET-52b(+)3C /LIC-p54 recombinant plasmid.
  • the pET-52b(+)3C/LIC-p54 recombinant plasmid obtained in the above step was transferred into Escherichia coli DH5 ⁇ , and inoculated on LB nutrient agar containing 100 mg/L ampicillin, and cultured at 37 ° C for 12 h, and a single colony was picked up. After incubating in LB liquid medium of 50 mg/L ampicillin for 12 hours at 37 ° C, the plasmid was extracted, and PCR identification and sequencing were performed to detect the integrity of the target gene.
  • PCR identification was performed using two pairs of primers, the first pair was the primer pair of Seq ID No. 2 and Seq ID No. 3, and the second pair was pET-52b(+)3C/LIC plasmid. Comes with a T7 primer pair.
  • the results of gel electrophoresis identified by PCR are shown in Figure 1.
  • the M lane is a DNA marker.
  • the lane 1 is the electrophoresis result of the first pair of primers PCR amplification
  • the lane 2 is the electrophoresis result of the second pair of primers PCR amplification;
  • the pET-52b(+)3C/LIC-p54 recombinant plasmid of this example is successfully constructed, and contains A target gene of about 462 bp is in line with theoretical expectations.
  • the sequencing results showed that the recombinant plasmid contained 462 bp of p54 gene, and its sequence was consistent with the sequence shown by Seq ID No. 10. This further confirmed that the pET-52b(+)3C/LIC-p54 recombinant plasmid constructed in this example contains what we need. P54 gene.
  • the front end of the p54 gene contains two promoters, and in this case, only one of the promoters was cloned in prokaryotic expression, that is, the nucleotide sequence of the signal peptide of the front end of the p54 gene of 90 bp was not cloned, so A pair of amplified target genes, Seq ID No. 2 and Seq ID No. 3, showed a primer size of 462 bp, and the gene also contained the entire gene sequence of the p54 protein, but did not contain a signal peptide of 90 bp in front. Nucleotide sequence; for this example, does not affect prokaryotic expression of the p54 protein.
  • BL21(DE3) bacterial competent cells were prepared, and the recombinant plasmid pET-52b(+)3C/LIC-p54 was transformed into BL21(DE3) cells, and then cultured on LB plate containing 100 mg/L ampicillin to pick up a single colony. Inoculated in 2 mL of LB medium containing 100 mg/L ampicillin, and cultured at 37 ° C, 200 r / min shaking shaker to an OD600 value of about 0.6. IPTG was added to a final concentration of 2 mM, and the bacterial solution was collected after 2 hours of culture. The culture solution was centrifuged at 4 ° C for 15 min, the supernatant was removed, and the cells were collected.
  • the pellet was resuspended in PBS, centrifuged at 10,000 g for 15 min at 4 ° C, and the supernatant was removed.
  • the cells were resuspended in a sterilizing buffer, sonicated on ice, centrifuged at 4 ° C for 15 min, and the supernatant was collected.
  • the expression product was stained with Coomassie brilliant blue by denaturing discontinuous SDS-PAGE, and the results were observed.
  • the M lane is the protein molecular mass standard; the lanes 1-5 are 0.5 mM, 1 mM, 2 mM, 4 mM, 8 mM IPTG induces pET-52b(+)3C/LIC-p54 two hours later.
  • the results of the analysis of the bacterial lysate supernatant were the results of the analysis of the bacterial lysate supernatant after two hours of pET-52b(+)3C/LIC-p54 induction without IPTG; the lanes of the bacteria were induced by 1 mM IPTG for two hours after BL21(DE3).
  • the results of the analysis of the lysed supernatant; the results of the analysis of the bacterial lysate supernatant after pET-52b(+)3C/LIC-p541h, 2h, 3h, 4h, and 5h were induced by 1 mM IPTG in lanes 8-12; 13 lanes were without IPTG.
  • the bacterial solution cultured in the above step was centrifuged at 4 ° C for 15 min, and the supernatant was removed to collect the cells.
  • the pellet was resuspended in PBS, centrifuged at 10,000 g for 15 min at 4 ° C, and the supernatant was removed.
  • the cells were resuspended in a sterilizing buffer, sonicated on ice, centrifuged at 4 ° C for 15 min, and the supernatant was collected.
  • the expression product was subjected to immunoblot analysis using African porcine standard positive serum to detect the antigenicity of the protein of interest. The results of immunoblot analysis are shown in Figure 3.
  • M is the molecular weight standard of the protein
  • 1 is the sample washing solution
  • 2 is the purified sample of the target protein
  • 3 is the sample lysate
  • 4 is the western blot analysis of the target protein; the result shows that the recombinant protein obtained in this example is indeed p54 recombination. protein.
  • the supernatant of the sonication on ice was purified by Ni column affinity chromatography, and the purified product, that is, the immunogen for p54, which is required in this example, was purified.
  • screening antigens were used to screen hybridoma cells.
  • One is the prokaryotic expression of p54 recombinant protein as the immunizing antigen in Example 1, and the p54 immunoprotein purified by nickel column is used as screening antigen.
  • the second is artificial synthesis.
  • the method of synthesizing the polypeptide represented by Seq ID No. 1; the third is to use the pFastBac/NT-TOPO insect expression system to express the p54 recombinant protein, and the supernatant of the infected recombinant baculovirus cells is used as a screening antigen.
  • the synthetic polypeptide represented by Seq ID No. 1 is based on the p54 protein sequence of all African swine fever viruses which have been disclosed in this example, and the polypeptide sequences shared by all African swine fever viruses, therefore, As a screening antigen, it is theoretically possible to screen out all monoclonal antibodies against African swine fever virus, and the results are shown in Fig. 7.
  • the specific preparation of the antigen is as follows:
  • Seq ID No. 1 SSRKKKAAAA IEEEDIQFINPYQDQQWAEV
  • the first group was the p54 gene amplification primer pair
  • the upstream primer NT-TOPO-ASFV54F was the sequence shown by Seq ID No. 4
  • the downstream primer NT-TOPO-ASFV54R was The sequence shown by Seq ID No. 5
  • the second set is a primer pair for PCR identification of the pFastBac/NT-TOPO-p54 recombinant plasmid
  • the upstream primer Polyhedrin forward primer is the sequence shown by Seq ID No. 6
  • the downstream primer SV40polyA reverse The primer is the sequence shown by Seq ID No. 7.
  • the third group is the primer pair for PCR identification of Bacmid-p54 recombinant cosmid.
  • the upstream primer pUC/M13Forward is the sequence shown by Seq ID No. 8, and the downstream primer pUC/M13Reverse The sequence shown in Seq ID No. 9.
  • Seq ID No. 4 5'-ATGGATTCTGAATTTTTTCAACC-3’
  • Seq ID No. 7 5'-GGTAT GGCTG ATTAT GATC-3’
  • Seq ID No. 8 5'-CCCAG TCACG ACGTT GTAAA ACG-3’
  • Seq ID No. 9 5'-AGCGG ATAAC AATTT CACAC AGG-3’
  • the same pMD18T-p54 recombinant plasmid as in Example 1 was used as a PCR template, and the p54 gene was amplified using the first set of primers, that is, the p54 gene amplification primer, and the PCR product was recovered using the PureLink HiPure Mini Plasmid Purification Kit to obtain the target gene. . 4 ⁇ L of the target gene was ligated to 1 ⁇ L of pFastBac/NT-TOPO vector, and then DH5 ⁇ competent cells were transformed.
  • PCR was performed on the NT-TOPO-ASFV54F and NT-TOPO-ASFV54R primers, which are the first set of primers.
  • the second is the use of primer pairs NT-TOPO-ASFV54F and SV40polyA reverse primer.
  • the results showed that the first set of primers amplified a fragment of about 552 bp, which was consistent with the expected 552 bp p54 gene.
  • the second set of primers amplified the fragment size of about 758 bp, indicating that the target gene has been ligated to the appropriate position of the vector, and the direction of the connection.
  • 10 ⁇ L of the recombinant plasmid pFastBac-p54 was transformed into E. coli DH 10Bac competent cells. After the transformation, 900 ⁇ L of LB medium was added to the EP tube, and cultured at 37 ° C for 4 hours at 225 rpm. The LB medium was diluted at a concentration of 1:10, 1:100, and 1:1000 at room temperature, and coated with 50 ⁇ g/mL kanamycin (hereinafter referred to as K+) and 7 ⁇ g/mL gentamicin.
  • K+ 50 ⁇ g/mL kanamycin
  • G+ 10 ⁇ g/mL tetracycline
  • Tet+ 10 ⁇ g/mL tetracycline
  • Bacmid-CAT and Bacmid-HTA were subjected to the same operation, and were set as positive and negative controls, respectively.
  • One part of the bacterial solution was taken out, and Bacmid was extracted using a large plasmid extraction kit PureLink HiPure Plasmid DNA Miniprep Kit, and the remaining bacterial liquid was stored at 4 °C.
  • PCR was performed using two sets of primers: one was to use the first set of primers to amplify the target gene primers for PCR of NT-TOPO-ASFV54F and NT-TOPO-ASFV54R; the other was to use the third set of primers, ie primer pair pUC /M13Forward and pUC/M13Reverse perform PCR.
  • a partial gel electrophoresis pattern of the PCR amplification product is shown in Figure B, where M is DNA Marker, and 3 is the amplification product of the first set of primers, namely primer pair NT-TOPO-ASFV54F and NT-TOPO-ASFV54R, 4 is the amplification product of the third set of primers, ie, primer pair pUC/M13Forward and pUC/M13Reverse, and 5 is a negative control.
  • the first set of primers amplified a fragment of about 552 bp, which was consistent with the expected 552 bp p54 gene; the third set of primers amplified a fragment of about 2988 bp, indicating that the p54 gene has been ligated to the baculovirus vector.
  • the remaining bacterial solution stored at 4 ° C was prepared into glycerol bacteria and frozen at -80 °C.
  • the IIReagent Transfection Kit instructions were used to lipidate Bacmid-p54, Bacmid-CAT, Bacmid-HTA.
  • Sf9 insect cells were transfected after lipidation, while normal Sf9 insect cells not transfected with Bacmid DNA were used as blank controls.
  • the cells were cultured in a 28 ° C incubator for approximately 72 h, during which time the cytopathic condition was observed. After about 36 hours, the cells showed lesions, and 80% of the cells showed lesions around 72 hours, and the cell culture supernatant was collected, which contained the recombinant baculovirus.
  • the supernatant was re-infected with normal cells, and the cytopathic condition was observed. 80% of the cells developed lesions in about 72 hours, and the supernatant and cells were collected.
  • the cells infected with the recombinant baculovirus were sonicated and the supernatant was extracted as a screening antigen.
  • the screening antigen was identified by Western-blot. The results are shown in Figure 5.
  • M is the protein marker
  • 1 is the normal sf9 cell protein
  • 2 is the p54 recombinant protein.
  • the results show that the supernatant contains the expected eukaryotic expression.
  • the purified p54 immunoprotein prepared in Example 1 was mixed with an equal amount of Freund's complete adjuvant and emulsified, and 7-week-old BALB/c female mice, 0.2 ⁇ g each, were injected subcutaneously. After 14 days, an equal amount of Freund's incomplete adjuvant was mixed with p54 protein and emulsified, and subcutaneous injection was performed. After 21 days, an equal amount of Freund's incomplete adjuvant was mixed with p54 protein and emulsified, and subcutaneous injection was performed. A booster injection without any adjuvant was performed 3 days prior to the planned and SP2/0 cell fusion.
  • mice with high titer were mixed with SP2/0 myeloma cells in a ratio of 10:1, and hybridoma cells were prepared by conventional PEG fusion method.
  • the supernatant of each well of hybridoma cells was detected by indirect ELISA using the screening antigen prepared in Example 2, and Escherichia coli and Sf9 cell proteins were used as negative controls for screening antigens.
  • the wells satisfying the indirect ELISA results of the three screening antigens in Example 2 were taken, subcloned by the limiting dilution method, the hybridoma cells were diluted 5 times and the monoclonal antibody test was repeated 5 times, and the last 3 times. In the antibody test, all the positive rate holes were 100%, and a hybridoma cell strain stably secreting monoclonal antibodies was obtained.
  • the reagent in the Sigma monoclonal antibody subclass identification kit will be returned to room temperature.
  • 500 ⁇ L of the buffer solution is added first, then 500 ⁇ L of the collected mouse ascites is added, and the small test tube is gently shaken to make the test paper.
  • the card is fully submerged.
  • Add 1 mL of anti-mouse antibody colloidal gold conjugate keep the word side of the test paper card immersed in the liquid, and gently shake the small tube at room temperature until a small spot appears. It was identified that the monoclonal antibody secreted by this hybridoma cell was an IgG1 subclass, which was consistent with expectations.
  • the common monoclonal antibody of African swine fever virus strain prepared by this example was used.
  • the antibody was detected as an antibody by indirect ELISA.
  • the results showed that the universal monoclonal antibody of the African swine fever virus strain prepared in this example did not cross-react with the above-mentioned common swine pathogens and had good specificity.
  • the affinity between the universal monoclonal antibody of the African swine fever virus strain prepared in this example and the specific antigen epitope polypeptide A in the African swine fever virus p54 protein was investigated to determine the antigen-antibody relationship. The degree of dissociation is combined to determine the stability of the antigen-antibody complex.
  • the chip was activated, and the universal monoclonal antibody of the African swine fever virus strain prepared in this example was chemically bonded to the chip, and then the chip was deactivated and tested for the binding of the monoclonal antibody.
  • the formulated different concentrations of polypeptide A were used as the liquid phase, and the solid phase chip combined with the monoclonal antibody was passed at a flow rate of 25 ⁇ L/min. When the antigen-antibody binding peaked, the antigen-antibody complex was dissociated and tested for dissociation. rate.
  • the abscissa 0s-150s is the mutual binding effect of different concentrations of polypeptide A and monoclonal antibody
  • 150s-500s is the dissociation of the antigen-antibody complex
  • 1 is the polypeptide A with a concentration of 150nM
  • 2 is a polypeptide having a concentration of 75 nM
  • A is a polypeptide having a concentration of 37.5 nM
  • 4 is a polypeptide having a concentration of 18.75 nM
  • 5 is a polypeptide having a concentration of 9.375 nM
  • 6 is a PBST buffer.
  • the equilibrium binding constant (KD) is 2.97 ⁇ 10-9M, and the binding rate constant (Ka) is 2.06 ⁇ 1051/Ms; indicating the universal monoclonal antibody and specific epitope polypeptide of the African swine fever virus strain prepared in this example.
  • A has a good combination and strong affinity, which is suitable for detection and diagnosis.
  • African porcine standard positive sera were purchased from the IAH Pirbright laboratory in the United Kingdom; 153 negative sera were collected from multiple farms in the country; c-ELISA commercial kits were purchased from INGENASA, Spain.
  • the universal monoclonal antibody of the African swine fever virus strain prepared in Example 3 was labeled with horseradish peroxidase (HRP) and stored at -80 °C until use.
  • HRP horseradish peroxidase
  • the P54 immune protein antigen was diluted to 2.5 ⁇ g/mL with a coating solution, and added to a 96-well microtiter plate, 100 ⁇ L per well, placed in a refrigerator at 4 ° C overnight, or at 37 ° C for 1 h.
  • Washing the plate Remove the enzyme-labeled plate and discard the liquid. Add 200 ⁇ L of the washing solution to each well and wash the plate for three times. The last time it was inverted and patted dry.
  • Blocking 100 ⁇ L of blocking solution was added to each well, and reacted at 37 ° C for 1 h to wash the plate.
  • Sample and weak positive control, positive control, negative control were diluted 1:5 with dilution, mixed, added to ELISA plate, 50 ⁇ L per well; react at 37 ° C for 1 h, wash the plate.
  • the reaction was terminated: the reaction plate was taken out, and 50 ⁇ L of the stop solution was quickly added to each well, and the OD value was measured within 30 minutes.
  • Absorbance value The absorbance was measured at 450 nm using a microplate reader.
  • the purified p54 was coated in a concentration gradient: 5, 2.5, 1.25, 0.625 ⁇ g/mL, 50 ⁇ L/well, and coated at 4 ° C overnight.
  • the optimal coating concentration is selected by the cost and the number of enzyme-labeled monoclonal antibodies.
  • PI (%) (1 - sample serum mean OD value ⁇ negative serum control mean OD value) ⁇ 100%
  • the average PI value of 20 sera and its standard deviation S were calculated.
  • the value of the average PI value plus the standard deviation S of 3 times is used as a positive result to determine the critical value; the average PI value plus the value of the standard deviation S of 2 times is used as a negative result determination threshold value; and between the two, it is determined as a suspicious sample.
  • the purified p54 was coated in a concentration gradient: 5, 2.5, 1.25, 0.625 ⁇ g/mL, 50 ⁇ L/well, and coated at 4 ° C overnight.
  • the above-mentioned enzyme standard monoclonal antibody was diluted in a vertical ratio: 25 ⁇ -3200 ⁇ , 0.5 h at 37° C., color development for 3 min, and 50 ⁇ L/well of 0.5 M sulfuric acid was added to terminate the color development.
  • the results are shown in Table 1.
  • the protein coating concentration at the OD450nm was about 1.5 and the concentration of the monoclonal antibody was measured.
  • the results of the monoclonal antibody titer were determined, and the experimental combination with less antigen and antibody dosage was considered as the optimal working condition to determine the optimal coating concentration of the protein. 2.5 ⁇ g/mL.
  • the inhibition rate was calculated, and the dilution ratio of the monoclonal antibody with the highest inhibition rate was taken as the optimal working concentration of the enzyme monoclonal antibody.
  • the enzyme-labeled monoclonal antibody was diluted 100-fold, the positive serum had the highest inhibition rate, so the dilution factor of the enzyme-labeled monoclonal antibody was selected as 100 times as the optimal enzyme-labeled monoclonal antibody working concentration.
  • the competitive ELISA method established by the universal monoclonal antibody of the African swine fever virus strain prepared in this example can effectively detect the African swine fever virus strains from different geographical sources, and the detection rate is 100%, and there is no missed detection.
  • the universal monoclonal antibody of African swine fever virus strain and its competitive ELISA method can effectively replace the imported kit, establish a detection reagent in line with international trade and an animal disease monitoring method suitable for China's national conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps monoclonal général de souches du virus de la peste porcine africaine ainsi qu'un de ses procédés de préparation. Le procédé consiste à : immuniser une souris à l'aide d'une protéine immunitaire p54 purifiée, fusionner des cellules de rate, provenant de la souris immunisée, avec des cellules de myélome pour préparer des cellules d'hybridomes, cribler avec trois antigènes de criblage de manière à obtenir les cellules d'hybridomes qui peuvent sécréter de manière stable un anticorps monoclonal, et ensuite préparer l'anticorps monoclonal à l'aide d'un procédé in vivo ou in vitro, les trois antigènes de criblage comprenant une protéine de recombinaison p54 exprimée à la façon d'un procaryote, une protéine de recombinaison p54 exprimée à la façon d'un eucaryote et un polypeptide synthétisé de manière artificielle représenté dans la SEQ ID No : 1.
PCT/CN2015/075183 2014-12-05 2015-03-27 Anticorps monoclonal général de souches du virus de la peste porcine africaine ainsi que son procédé de préparation et application associée WO2016086554A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410736335.XA CN104497137B (zh) 2014-12-05 2014-12-05 非洲猪瘟病毒毒株通用单克隆抗体及制备方法和应用
CN201410736335.X 2014-12-05

Publications (1)

Publication Number Publication Date
WO2016086554A1 true WO2016086554A1 (fr) 2016-06-09

Family

ID=52938604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/075183 WO2016086554A1 (fr) 2014-12-05 2015-03-27 Anticorps monoclonal général de souches du virus de la peste porcine africaine ainsi que son procédé de préparation et application associée

Country Status (2)

Country Link
CN (1) CN104497137B (fr)
WO (1) WO2016086554A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937349A (zh) * 2017-11-27 2018-04-20 中国检验检疫科学研究院 稳定表达非洲猪瘟病毒p54蛋白的细胞系及其制备与应用
CN109517072A (zh) * 2018-11-20 2019-03-26 杭州贤至生物科技有限公司 一种伤寒杆菌重组蛋白及其单克隆抗体的制备
CN109735567A (zh) * 2019-01-18 2019-05-10 扬州大学 一种非洲猪瘟ep153r与p54基因共表达的重组腺病毒载体构建及腺病毒包装方法
CN110423761A (zh) * 2019-07-08 2019-11-08 郑州大学 一种非洲猪瘟病毒抗体检测试纸
CN111849922A (zh) * 2020-07-20 2020-10-30 华中农业大学 一种非洲猪瘟病毒截短蛋白p54制备的单克隆抗体及其应用
CN112444626A (zh) * 2019-08-30 2021-03-05 洛阳普泰生物技术有限公司 一种非洲猪瘟病毒抗体elisa检测试剂盒及其制备方法
CN113607952A (zh) * 2021-08-18 2021-11-05 杭州恒奥科技有限公司 非洲猪瘟病毒阻断elisa抗体检测试剂盒及其制备方法和应用
CN115724991A (zh) * 2022-02-23 2023-03-03 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 可溶性表达的重组蛋白rP22、杂交瘤细胞株及其应用
CN115819564A (zh) * 2022-12-19 2023-03-21 四川大学 一种检测非洲猪瘟的单链抗体、试剂盒及方法
CN115925887A (zh) * 2022-10-27 2023-04-07 华中农业大学 非洲猪瘟病毒pA104R蛋白免疫优势性B细胞抗原表位及其单克隆抗体与应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810948B (zh) * 2019-01-18 2021-09-17 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒k205r蛋白单克隆抗体的杂交瘤细胞株及其分泌的抗体
CN109734810A (zh) * 2019-01-24 2019-05-10 深圳市雅臣智能生物工程有限公司 抗非洲猪瘟病毒和cd双靶标猪源化抗体、制备法和应用
CN111925436B (zh) * 2019-11-29 2021-05-18 洛阳普泰生物技术有限公司 非洲猪瘟病毒p30蛋白的单克隆抗体及其应用
CN111549001B (zh) * 2020-05-28 2024-04-19 嘉铭(固安)生物科技有限公司 分泌非洲猪瘟病毒p34蛋白单克隆抗体的杂交瘤细胞株、单克隆抗体及应用
CN112481220B (zh) * 2020-11-03 2021-09-14 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒解旋酶d1133l单克隆抗体、分泌该单克隆抗体的杂交瘤细胞株及应用
CN112661817B (zh) * 2020-12-25 2022-05-17 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒p54蛋白单克隆抗体的制备方法、表位鉴定及应用
CN113045673B (zh) * 2021-03-25 2021-11-23 深圳海关动植物检验检疫技术中心 一种基于嵌合p54抗原表位的非洲猪瘟病毒抗体检测试剂盒及应用
CN113402601A (zh) * 2021-06-09 2021-09-17 河南中泽生物工程有限公司 一种抗非洲猪瘟病毒p54蛋白单克隆抗体的制备方法及应用
CN114167055B (zh) * 2021-10-21 2023-07-18 山东绿都生物科技有限公司 一种用于检测血清中抗非洲猪瘟抗体的竞争酶联免疫试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101818129A (zh) * 2010-04-23 2010-09-01 天津出入境检验检疫局动植物与食品检测中心 一种抗非洲猪瘟病毒单克隆抗体的杂交瘤细胞系及其所分泌的单克隆抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101831407B (zh) * 2010-04-23 2012-06-06 天津出入境检验检疫局动植物与食品检测中心 抗非洲猪瘟病毒单克隆抗体的杂交瘤细胞系及其所分泌的单克隆抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101818129A (zh) * 2010-04-23 2010-09-01 天津出入境检验检疫局动植物与食品检测中心 一种抗非洲猪瘟病毒单克隆抗体的杂交瘤细胞系及其所分泌的单克隆抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAO, CH .F. ET AL.: "Prokaryotic Expression of P54 Gene of African Swine Fever Virus and Establishment of Indirect Elisa for Detection of Its Antibody Against p54", PROGRESS IN VETERINARY MEDICINE, vol. 2, no. 35, 20 February 2014 (2014-02-20), pages 6 - 10, ISSN: 1007-5038 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937349A (zh) * 2017-11-27 2018-04-20 中国检验检疫科学研究院 稳定表达非洲猪瘟病毒p54蛋白的细胞系及其制备与应用
CN109517072A (zh) * 2018-11-20 2019-03-26 杭州贤至生物科技有限公司 一种伤寒杆菌重组蛋白及其单克隆抗体的制备
CN109735567A (zh) * 2019-01-18 2019-05-10 扬州大学 一种非洲猪瘟ep153r与p54基因共表达的重组腺病毒载体构建及腺病毒包装方法
CN110423761B (zh) * 2019-07-08 2022-07-05 郑州大学 一种非洲猪瘟病毒抗体检测试纸
CN110423761A (zh) * 2019-07-08 2019-11-08 郑州大学 一种非洲猪瘟病毒抗体检测试纸
CN112444626A (zh) * 2019-08-30 2021-03-05 洛阳普泰生物技术有限公司 一种非洲猪瘟病毒抗体elisa检测试剂盒及其制备方法
CN112444626B (zh) * 2019-08-30 2023-09-12 洛阳普泰生物技术有限公司 一种非洲猪瘟病毒抗体elisa检测试剂盒及其制备方法
CN111849922A (zh) * 2020-07-20 2020-10-30 华中农业大学 一种非洲猪瘟病毒截短蛋白p54制备的单克隆抗体及其应用
CN111849922B (zh) * 2020-07-20 2021-08-03 华中农业大学 一种非洲猪瘟病毒截短蛋白p54制备的单克隆抗体及其应用
CN113607952B (zh) * 2021-08-18 2022-03-11 杭州恒奥科技有限公司 非洲猪瘟病毒阻断elisa抗体检测试剂盒及其制备方法和应用
CN113607952A (zh) * 2021-08-18 2021-11-05 杭州恒奥科技有限公司 非洲猪瘟病毒阻断elisa抗体检测试剂盒及其制备方法和应用
CN115724991A (zh) * 2022-02-23 2023-03-03 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 可溶性表达的重组蛋白rP22、杂交瘤细胞株及其应用
CN115925887A (zh) * 2022-10-27 2023-04-07 华中农业大学 非洲猪瘟病毒pA104R蛋白免疫优势性B细胞抗原表位及其单克隆抗体与应用
CN115925887B (zh) * 2022-10-27 2024-02-09 华中农业大学 非洲猪瘟病毒pA104R蛋白免疫优势性B细胞抗原表位及其单克隆抗体与应用
CN115819564A (zh) * 2022-12-19 2023-03-21 四川大学 一种检测非洲猪瘟的单链抗体、试剂盒及方法
CN115819564B (zh) * 2022-12-19 2023-11-14 四川大学 一种检测非洲猪瘟的单链抗体、试剂盒及方法

Also Published As

Publication number Publication date
CN104497137B (zh) 2017-10-31
CN104497137A (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
WO2016086554A1 (fr) Anticorps monoclonal général de souches du virus de la peste porcine africaine ainsi que son procédé de préparation et application associée
CN109796531B (zh) 猪Delta冠状病毒N蛋白单克隆抗体及其抗原表位和应用
WO2020200143A1 (fr) Lignée cellulaire d'hybridome destinée à sécréter un anticorps monoclonal anti-rabique agissant sur la protéine m, et son utilisation
CN108546288B (zh) 一种人轮状病毒vp8重组蛋白以及利用该vp8重组蛋白的人用轮状病毒疫苗
US11376319B2 (en) Recombinant H7N9 subtype avian influenza virus, inactivated marked vaccine and preparation method thereof
CN112574318B (zh) 非洲猪瘟病毒p22蛋白纳米颗粒及其制备方法与应用
CN109867727B (zh) 一种flagellin-fiber2融合蛋白、其制备方法和应用
WO2022257237A1 (fr) Nouvel antigène polypeptidique à large spectre du coronavirus sras-cov -2 et anticorps neutralisant spécifique et son utilisation
Zhang et al. Identification of linear B cell epitope on gB, gC, and gE proteins of porcine pseudorabies virus using monoclonal antibodies
CN104497136A (zh) 非洲猪瘟病毒基因ii型毒株单克隆抗体及制备方法和应用
CN103304642A (zh) 猪轮状病毒δvp8*亚单位重组蛋白及其应用
CN114874995B (zh) 猪瘟病毒2型Erns蛋白的单克隆抗体杂交瘤细胞株及应用
KR100593213B1 (ko) 곤충세포발현 재조합 ｎ 단백질 및 ｎ 단백질에 대한 단클론항체를 이용한 가성우역의 신속진단방법
Martinez et al. Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice
CN112574319A (zh) 非洲猪瘟病毒p12蛋白纳米颗粒及其制备方法与应用
Chen et al. Surface display of peptides corresponding to the heptad repeat 2 domain of the feline enteric coronavirus spike protein on Bacillus Subtilis spores elicits protective immune responses against homologous infection in a feline aminopeptidase-N-transduced mouse model
CN110257405B (zh) 牛支原体乙醇脱氢酶基因及其编码蛋白与应用
Hou et al. Characterization and diagnostic use of a monoclonal antibody for VP28 envelope protein of white spot syndrome virus
CN107460173B (zh) 一种纯化猪流行性腹泻病毒、猪繁殖与呼吸综合征病毒或禽流感病毒的方法
CN113234654B (zh) 一种重组枯草芽孢杆菌及其应用
Yang et al. Phylogeny and expression of the nucleocapsid gene of porcine epidemic diarrhoea virus
CN107163108B (zh) 一种伪狂犬病病毒gE蛋白的抗原表位、抗体的制备及应用
CN107619435B (zh) 一种猪瘟病毒e2蛋白的抗原表位、抗体的制备及应用
CN110894216A (zh) 一种猪流行性腹泻病毒抗原表位肽、单克隆抗体及应用
CN112522210B (zh) 一种分泌抗小反刍兽疫病毒单克隆抗体的杂交瘤细胞株及其单抗与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15865141

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15865141

Country of ref document: EP

Kind code of ref document: A1